A Randomized, Phase II Trial of Standard Triweekly Compared with Dose-Dense Biweekly Capecitabine Plus Oxaliplatin Plus Bevacizumab as First-Line Treatment for Metastatic Colorectal Cancer: XELOX-A-DVS (Dense Versus Standard)

BACKGROUND. Capecitabine administered for 7 days biweekly with oxaliplatin (XELOX) biweekly has been reported to have activity and safety profiles similar to those of standard capecitabine given for 14 days triweekly. Multiple studies have shown that the addition of bevacizumab to 5-fluorouracil–bas...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Hurwitz, Herbert, Mitchell, Edith P., Cartwright, Thomas, Kwok, Ambrose, Hu, Sylvia, McKenna, Edward, Patt, Yehuda Z.
Format: Artigo
Jezik:Inglês
Izdano: AlphaMed Press 2012
Teme:
Gastrointestinal Cancer
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3399650/
https://ncbi.nlm.nih.gov/pubmed/22622147
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0071
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki